TY - JOUR
TI - Effects of two combined monophasic and triphasic ethinylestradiol/ gestodene oral contraceptives on natural inhibitors and other hemostatic variables
AU - Creatsas, G.
AU - Kontopoulou-Griva, I.
AU - Deligeoroglou, E.
AU - Digenopoulou, L.
AU - Tsangaris, A.
AU - Kallipolitis, G.
AU - Milingos, S.
AU - Michalas, S.
JO - The European Journal of Contraception and Reproductive Health Care
PY - 1997
VL - 2
TODO - 1
SP - 31-38
PB - LIBRAPHARM/INFORMA HEALTHCARE
SN - 1362-5187, 1473-0782
TODO - 10.1080/13625189709049932
TODO - antithrombin III;  estradiol derivative;  ethinylestradiol;  fibrinogen;  gestodene;  lupus anticoagulant;  oral contraceptive agent;  plasminogen;  pregnane derivative;  progesterone derivative;  protein C, adolescent;  adult;  article;  blood;  clinical trial;  comparative study;  drug effect;  female;  hemostasis;  human;  prothrombin time;  randomized controlled trial;  time, Adolescent;  Adult;  Antithrombin III;  Contraceptives, Oral, Combined;  Contraceptives, Oral, Synthetic;  Estradiol Congeners;  Ethinyl Estradiol;  Female;  Fibrinogen;  Hemostasis;  Humans;  Lupus Coagulation Inhibitor;  Norpregnenes;  Plasminogen;  Progesterone Congeners;  Protein C;  Prothrombin Time;  Time Factors
TODO - Objective: To evaluate the effects of two preparations of combined oral contraceptives (COCs), the monophasic COC containing 30 μg ethinylestradiol and 75 μg gestodene and the triphasic COC containing 30/40/30 ethinylestradiol and 50/70/100 μg gestodene on seven natural inhibitors and hemostatic variables. Method: Forty-four healthy young women, randomly allocated into two groups (A and B) received the two preparations of COCs, respectively. The following variables were tested in a basic examination and at 1-, 3- and 6-month intervals to evaluate the role of the above preparations on the hemostatic balance of prothrombin time, fibrinogen, antithrombin III activity, protein C activity, total protein S antigen, plasminogen activity and lupus anticoagulant. Results: Group A women presented shorter prothrombin time at 6 months, an increased fibrinogen level at 3 months, no influence on the anticoagulant factors, antithrombin III, protein C and total protein S and an increased plasminogen activity at the 1st and 3rd months of treatment. On the other hand, group B women presented shorter prothrombin time at 3 months, no increase in fibrinogen, a decrease in antithrombin III activity and total protein S activity at the 6th month, whereas protein C and plasminogen activities were found to be increased at the 3rd and 1st, 3rd and 6th month, respectively. Conclusions: The study did not find differences between the two treatment groups, for the evaluated parameters. This finding is clearly important in the light of the recent epidemiological reports on third-generation COCs. However, differences were found among the various periods of administration of both COCs.
ER -